Abstract
Because of the poor prognosis for patients with esophageal cancer and the risks associated with surgical intervention, accurate staging is essential for optimal treatment planning. Positron emission tomography （PET） with ^18F-fluorodeoxyglucose （FDG） is a useful adjunct to more conventional imaging modalities in this setting. ^18F-FDG PET is not an appropriate first-line diagnostic procedure in the detection of esophageal cancer and is not helpful in detecting local invasion by the primary tumor. However, ^18F-FDG PET is superior to anatomic imaging modalities in the ability to detect distant metastases. Metastases to the liver, lungs, and skeleton can readily be identified at ^18F-FDG PET. In addition, ^18F-FDG PET has proved valuable in determining the respectability of disease and allows scanning of a larger volume, which is possible with computed tomography. Recurrent disease is readily diagnosed and differentiated from scar tissue with ^18F-FDG PET. In addition, ^18F-FDG PET may play a valuable role in the follow up of patients who undergo chemotherapy and radiation therapy, allowing early changes in treatment for unresponsive tumors. The management of most patients with esophageal cancer can be improved with the use of ^18F-FDG PET. Key words: Esophagus neoplasms; Tomography, emission-computed; Fludeoxyglucose F18; Tomography, X-ray computed
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
